Displaying drugs 676 - 700 of 773 in total
Matrix-M
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
Investigational
AG-858
AG-858 (autologous heat-shock protein 70 peptide vaccine) is
a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity...
Investigational
Matched Description: … HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing …
Indium In-111 satumomab pendetide
Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.
Experimental
Withdrawn
Odronextamab
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Matched Description: … PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor …
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
XTL-001
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV).
Investigational
OSE-2101
Investigational
ALLO-605
ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).
Investigational
Matched Description: … maturation antigen (BCMA). ... ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell …
CAR BCMA-CS1
CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.
Investigational
Matched Description: … B-cell maturation antigen and CS1. ... CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target …
105AD7
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Ligelizumab
Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). Similar in mechanism to omalizumab, another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer a greater affinity for free serum IgE and...
Investigational
Bisphenol Z
Experimental
Topsalysin
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
Investigational
KITE-585
KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational
Matched Description: … KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor …
Coltuximab ravtansine
Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).
Investigational
NKX101
NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational
Matched Description: … NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy. …
MT-401
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
Matched Description: … MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy. …
BG1805
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Investigational
Matched Description: … BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy. …
MK-4721
MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Investigational
Matched Description: … (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with ... 4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen …
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16 ... type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting …
Metampicillin
Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.
Experimental
Matched Iupac: … ]heptane-2-carboxylic acid ... (2S,5R,6R)-3,3-dimethyl-6-[(2R)-2-(methylideneamino)-2-phenylacetamido]-7-oxo-4-thia-1-azabicyclo[3.2.0 …
Matched Description: … Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
SGN-15
SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic. When it is combined with...
Investigational
MDX-1097
MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Investigational
Matched Description: … MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA). …
Displaying drugs 676 - 700 of 773 in total